Pathology: Commonly Monitored Glioblastoma Markers: EFGR, EGFRvIII, PTEN, and MGMT

Neurosurgery Clinics of North America

Volumn 23, Issue 2, 2012, Pages 237-246

  Camara Quintana, Joaquin Q ^a   Nitta, Ryan T ^a   Li, Gordon ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

EGFR; EGFRvIII; Glioblastoma; MGMT; PTEN

Indexed keywords

6 O BENZYLGUANINE; ADENOSINE TRIPHOSPHATE; BEVACIZUMAB; CARMUSTINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425; MONOCLONAL ANTIBODY 806; MONOCLONAL ANTIBODY Y10; NIMOTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE; RAPAMYCIN; RINDOPEPIMUT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BINDING SITE; CANCER PROGNOSIS; CANCER SURVIVAL; DNA METHYLATION; DRUG MECHANISM; DRUG TARGETING; GENE TARGETING; GLIOBLASTOMA; HUMAN; LIGAND BINDING; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NEUROSURGERY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; PROMOTER REGIONS, GENETIC; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84863361974     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.01.011     Document Type: Review

References (90)

1. Burger P.C., Vogel F.S., Green S.B., et al. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985, 56(5):1106-1111.
2. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 who classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2):97-109.
3. Wen P.Y., Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359(5):492-507.
4. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19(3):183-232.
5. Wells A. Egf receptor. Int J Biochem Cell Biol 1999, 31(6):637-643.
6. Citri A., Yarden Y. Egf-erbb signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7(7):505-516.
7. Hynes N.E., Lane H.A. Erbb receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5(5):341-354.
8. Libermann T.A., Nusbaum H.R., Razon N., et al. Amplification, enhanced expression and possible rearrangement of egf receptor gene in primary human brain tumours of glial origin. Nature 1985, 313(5998):144-147.
9. Wong A.J., Bigner S.H., Bigner D.D., et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 1987, 84(19):6899-6903.
10. Chakravarti A., Chakladar A., Delaney M.A., et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a ras-dependent manner. Cancer Res 2002, 62(15):4307-4315.
11. Barker F.G., Simmons M.L., Chang S.M., et al. Egfr overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 51(2):410-418.
12. Watanabe K., Tachibana O., Sata K., et al. Overexpression of the egf receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996, 6(3):217-223. [discussion: 23-4].
13. Cohen K.A., Liu T., Bissonette R., et al. Dab389egf fusion protein therapy of refractory glioblastoma multiforme. Curr Pharm Biotechnol 2003, 4(1):39-49.
14. Halatsch M.E., Schmidt U., Botefur I.C., et al. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger rna. J Neurosurg 2000, 92(2):297-305.
15. Liu T.F., Hall P.D., Cohen K.A., et al. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 2005, 11(1):329-334.
16. Lorimer I.A., Keppler-Hafkemeyer A., Beers R.A., et al. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A 1996, 93(25):14815-14820.
17. Kang C.S., Zhang Z.Y., Jia Z.F., et al. Suppression of egfr expression by antisense or small interference rna inhibits u251 glioma cell growth in vitro and in vivo. Cancer Gene Ther 2006, 13(5):530-538.
18. Vollmann A., Vornlocher H.P., Stempfl T., et al. Effective silencing of egfr with rnai demonstrates non-egfr dependent proliferation of glioma cells. Int J Oncol 2006, 28(6):1531-1542.
19. Yamazaki H., Kijima H., Ohnishi Y., et al. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 1998, 90(8):581-587.
20. Razis E., Selviaridis P., Labropoulos S., et al. Phase ii study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 2009, 15(19):6258-6266.
21. Thiessen B., Stewart C., Tsao M., et al. A phase i/ii trial of gw572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2010, 65(2):353-361.
22. Raizer J.J., Abrey L.E., Lassman A.B., et al. A phase ii trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 2010, 12(1):95-103.
23. van den Bent M.J., Brandes A.A., Rampling R., et al. Randomized phase ii trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: eortc brain tumor group study 26034. J Clin Oncol 2009, 27(8):1268-1274.
24. Wong E.T., Hess K.R., Gleason M.J., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase ii clinical trials. J Clin Oncol 1999, 17(8):2572-2578.
25. Rich J.N., Reardon D.A., Peery T., et al. Phase ii trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22(1):133-142.
26. Uhm J.H., Ballman K.V., Wu W., et al. Phase ii evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: mayo/north central cancer treatment group study n0074. Int J Radiat Oncol Biol Phys 2011, 80(2):347-353.
27. Reardon D.A., Quinn J.A., Vredenburgh J.J., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006, 12(3 Pt 1):860-868.
28. Reardon D.A., Desjardins A., Vredenburgh J.J., et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 2010, 96(2):219-230.
29. Kreisl T.N., Lassman A.B., Mischel P.S., et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (gbm). J Neurooncol 2009, 92(1):99-105.
30. Eller J.L., Longo S.L., Kyle M.M., et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 2005, 56(1):155-162. [discussion: 62].
31. Patel D., Lahiji A., Patel S., et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor viii on the cell surface. Anticancer Res 2007, 27(5A):3355-3366.
32. Eller J.L., Longo S.L., Hicklin D.J., et al. Activity of anti-epidermal growth factor receptor monoclonal antibody c225 against glioblastoma multiforme. Neurosurgery 2002, 51(4):1005-1013. [discussion: 13-4].
33. Neyns B., Sadones J., Joosens E., et al. Stratified phase ii trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009, 20(9):1596-1603.
34. Hasselbalch B., Lassen U., Hansen S., et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase ii trial. Neuro Oncol 2010, 12(5):508-516.
35. Ramos T.C., Figueredo J., Catala M., et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (egfr) antibody h-r3: report from a phase i/ii trial. Cancer Biol Ther 2006, 5(4):375-379.
36. Quang T.S., Brady L.W. Radioimmunotherapy as a novel treatment regimen: 125i-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 2004, 58(3):972-975.
37. Humphrey P.A., Wong A.J., Vogelstein B., et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990, 87(11):4207-4211.
38. Wong A.J., Ruppert J.M., Bigner S.H., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992, 89(7):2965-2969.
39. Frederick L., Wang X.Y., Eley G., et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000, 60(5):1383-1387.
40. Fernandes H., Cohen S., Bishayee S. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (egfrviii/deltaegfr) expressed in cancer cells. J Biol Chem 2001, 276(7):5375-5383.
41. Antonyak M.A., Moscatello D.K., Wong A.J. Constitutive activation of c-jun n-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 1998, 273(5):2817-2822.
42. Moscatello D.K., Holgado-Madruga M., Emlet D.R., et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998, 273(1):200-206.
43. Moscatello D.K., Holgado-Madruga M., Godwin A.K., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55(23):5536-5539.
44. Galanis E., Buckner J., Kimmel D., et al. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 1998, 13(4):717-724.
45. Newcomb E.W., Cohen H., Lee S.R., et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, egfr, mdm2 or bcl-2 genes. Brain Pathol 1998, 8(4):655-667.
46. Waha A., Baumann A., Wolf H.K., et al. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. J Neurosurg 1996, 85(4):634-641.
47. Bouvier-Labit C., Chinot O., Ochi C., et al. Prognostic significance of ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 1998, 24(5):381-388.
48. Etienne M.C., Formento J.L., Lebrun-Frenay C., et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 1998, 4(10):2383-2390.
49. Zhu A., Shaeffer J., Leslie S., et al. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 1996, 34(4):809-815.
50. Heimberger A.B., Hlatky R., Suki D., et al. Prognostic effect of epidermal growth factor receptor and egfrviii in glioblastoma multiforme patients. Clin Cancer Res 2005, 11(4):1462-1466.
51. Heimberger A.B., Suki D., Yang D., et al. The natural history of egfr and egfrviii in glioblastoma patients. J Transl Med 2005, 3:38.
52. Johns T.G., Stockert E., Ritter G., et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (egfr) that also recognizes the egfr expressed in cells containing amplification of the egfr gene. Int J Cancer 2002, 98(3):398-408.
53. Jungbluth A.A., Stockert E., Huang H.J., et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 2003, 100(2):639-644.
54. Perera R.M., Narita Y., Furnari F.B., et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005, 11(17):6390-6399.
55. Sampson J.H., Crotty L.E., Lee S., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 2000, 97(13):7503-7508.
56. Ochiai H., Archer G.E., Herndon J.E., et al. Egfrviii-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of cd4+ and cd8+ t cells. Cancer Immunol Immunother 2008, 57(1):115-121.
57. Yang W., Wu G., Barth R.F., et al. Molecular targeting and treatment of composite egfr and egfrviii-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res 2008, 14(3):883-891.
58. Ciesielski M.J., Kazim A.L., Barth R.F., et al. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 2005, 54(2):107-119.
59. Heimberger A.B., Archer G.E., Crotty L.E., et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 2002, 50(1):158-164. [discussion: 64-6].
60. Heimberger A.B., Crotty L.E., Archer G.E., et al. Epidermal growth factor receptor viii peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003, 9(11):4247-4254.
61. Moscatello D.K., Ramirez G., Wong A.J. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 1997, 57(8):1419-1424.
62. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
63. Sampson J.H., Aldape K.D., Archer G.E., et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate egfrviii-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011, 13(3):324-333.
64. Li J., Yen C., Liaw D., et al. Pten, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275(5308):1943-1947.
65. Fraser M.M., Zhu X., Kwon C.H., et al. Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 2004, 64(21):7773-7779.
66. Gottschalk A.R., Basila D., Wong M., et al. P27kip1 is required for pten-induced g1 growth arrest. Cancer Res 2001, 61(5):2105-2111.
67. Furnari F.B., Huang H.J., Cavenee W.K. The phosphoinositol phosphatase activity of pten mediates a serum-sensitive g1 growth arrest in glioma cells. Cancer Res 1998, 58(22):5002-5008.
68. Backman S.A., Stambolic V., Suzuki A., et al. Deletion of pten in mouse brain causes seizures, ataxia and defects in soma size resembling lhermitte-duclos disease. Nat Genet 2001, 29(4):396-403.
69. Kwon C.H., Zhu X., Zhang J., et al. Pten regulates neuronal soma size: a mouse model of lhermitte-duclos disease. Nat Genet 2001, 29(4):404-411.
70. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9(3):157-173.
71. Raffel C., Frederick L., O'Fallon J.R., et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with pten mutations. Clin Cancer Res 1999, 5(12):4085-4090.
72. Homma T., Fukushima T., Vaccarella S., et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006, 65(9):846-854.
73. Lin H., Bondy M.L., Langford L.A., et al. Allelic deletion analyses of mmac/pten and dmbt1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 1998, 4(10):2447-2454.
74. Tada K., Shiraishi S., Kamiryo T., et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg 2001, 95(4):651-659.
75. Zhou X.P., Li Y.J., Hoang-Xuan K., et al. Mutational analysis of the pten gene in gliomas: molecular and pathological correlations. Int J Cancer 1999, 84(2):150-154.
76. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to egfr kinase inhibitors. N Engl J Med 2005, 353(19):2012-2024.
77. Mineura K., Izumi I., Watanabe K., et al. Influence of o6-methylguanine-DNA methyltransferase activity on chloroethylnitrosourea chemotherapy in brain tumors. Int J Cancer 1993, 55(1):76-81.
78. Gerson S.L. Mgmt: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4(4):296-307.
79. Belanich M., Pastor M., Randall T., et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996, 56(4):783-788.
80. Jaeckle K.A., Eyre H.J., Townsend J.J., et al. Correlation of tumor o6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a southwest oncology group study. J Clin Oncol 1998, 16(10):3310-3315.
81. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of o-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10(6):1871-1874.
82. Everhard S., Kaloshi G., Criniere E., et al. Mgmt methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006, 60(6):740-743.
83. Hegi M.E., Diserens A.C., Gorlia T., et al. Mgmt gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
84. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase iii study: 5-year analysis of the eortc-ncic trial. Lancet Oncol 2009, 10(5):459-466.
85. Weller M., Felsberg J., Hartmann C., et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network. J Clin Oncol 2009, 27(34):5743-5750.
86. Shah N., Lin B., Sibenaller Z., et al. Comprehensive analysis of mgmt promoter methylation: correlation with mgmt expression and clinical response in gbm. PLoS One 2011, 6(1):e16146.
87. Krex D., Klink B., Hartmann C., et al. Long-term survival with glioblastoma multiforme. Brain 2007, 130(Pt 10):2596-2606.
88. Dunn J., Baborie A., Alam F., et al. Extent of mgmt promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009, 101(1):124-131.
89. Hegi M.E., Liu L., Herman J.G., et al. Correlation of o6-methylguanine methyltransferase (mgmt) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate mgmt activity. J Clin Oncol 2008, 26(25):4189-4199.
90. Sarkaria J.N., Kitange G.J., James C.D., et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008, 14(10):2900-2908.